Developing radionuclide PARP inhibitors Interviewee/Contributor Greg Mullen Organisation Theragnostics Ltd Cancer (Oncology) Drug discovery Personalised medicine Read more about Developing radionuclide PARP inhibitors
The linker matters in antibody-drug conjugates Interviewee/Contributor Philipp Spycher Organisation Araris Biotech AG Antibody Drug Conjugates ADCs Cancer (Oncology) Drug discovery Read more about The linker matters in antibody-drug conjugates
The hunt for the perfect tumour-associated antigen Interviewee/Contributor Erik Manting Organisation DCPrime BV Commentary Cancer (Oncology) Drug discovery Read more about The hunt for the perfect tumour-associated antigen
Finding a link between the microbiome and disease Interviewee/Contributor Steff Taelman Organisation BioLizard NV Drug discovery Read more about Finding a link between the microbiome and disease
The role of oncolytic viruses in immuno-oncology Interviewee/Contributor Bernard Huber and Paul Higham Organisation Oryx GmbH & Co KG and Valo Therapeutics Ltd Drug discovery Strategy Oncolytic viruses Read more about The role of oncolytic viruses in immuno-oncology
Investors support new antifungal agent Interviewee/Contributor Ralf Schmid and Emma Harvey Organisation F2G Ltd Drug discovery Finance Venture Capital Read more about Investors support new antifungal agent
Evox developes exosomes as therapeutics Interviewee/Contributor Antonin de Fougerolles Organisation Evox Therapeutics Ltd Drug discovery RNA Read more about Evox developes exosomes as therapeutics
Unlocking the potential of PSMA as a cancer target Interviewee/Contributor Brian McGuinness and Theodora Harold Organisation Crescendo Biologics Ltd Cancer (Oncology) Drug discovery Strategy Read more about Unlocking the potential of PSMA as a cancer target
Convalescent plasma hope in SARS-CoV-2 crisis Interviewee/Contributor Peter Charlish Organisation MedNous Antibody Drug discovery Read more about Convalescent plasma hope in SARS-CoV-2 crisis
What patients really want: involvement Interviewee/Contributor Pierre Meulien Organisation Innovative Medicines Initiative Commentary Clinical trials Drug discovery Policy & Regulation Read more about What patients really want: involvement